晚期肝细胞癌全身治疗的最新进展

StephenW

Recent Advances in Systemic Therapies for Advanced Hepatocellular Carcinoma

    Gabriella Aitcheson, Anjana Pillai, Bassam Dahman & Binu V John

Current Hepatology Reports volume 20, pages23–33(2021)Cite this article

    214 Accesses

    5 Altmetric

    Metrics details

Abstract
Purpose of Review

This paper aims to summarize the data of recently completed and key ongoing clinical trials of systemic agents for advanced hepatocellular carcinoma (aHCC). In particular, the review focuses on ongoing checkpoint inhibitor combination trials and promising studies combining tyrosine kinase inhibitors with checkpoint inhibitors.
Recent Findings

The recently approved combination of atezolizumab and bevacizumab based on the IMbrave150 trial has shown the most potential with the highest overall survival of any systemic agent in HCC to date, surpassing sorafenib. Despite COVID-19 delays, other promising trials that involve combining VEGF-directed therapy and checkpoint inhibition, cancer vaccines, phosphatidylserine, YIV-906, and oncolytic and immunotherapeutic vaccinia virus are actively recruiting patients.
Summary

After almost a 10-year dormancy, the list of potential systemic treatment options for aHCC is growing rapidly. Given the promising data from the IMbrave150 trial, the combination of atezolizumab and bevacizumab is now the new first-line therapy. We discuss the change in landscape, the new second- and third-line systemic treatments in aHCC, and the ongoing clinical trials for newer agents including combination therapies.

StephenW

晚期肝细胞癌全身治疗的最新进展

    加布里埃拉·艾奇逊（Gabriella Aitcheson），安妮娜·皮莱（Anjana Pillai），巴萨姆·达曼（Bassam Dahman）和比奴·V·约翰（Binu V John）

《当前肝病学报告》第20卷，第23–33（2021）页，引用本文

    214次访问

    5高度

    指标详细信息

抽象的
审查目的

本文旨在总结晚期肝细胞癌（aHCC）全身用药的最新完成和关键正在进行的临床试验数据。特别是，本综述着眼于正在进行的检查点抑制剂联合试验以及将酪氨酸激酶抑制剂与检查点抑制剂结合的有前途的研究。
最近的发现

根据IMbrave150试验，最近批准的atezolizumab和bevacizumab的组合显示，迄今为止，肝癌中任何全身性药物的最大生存潜力和最高总生存率均超过索拉非尼。尽管延迟了COVID-19，但其他有前途的试验正在积极招募患者，这些试验涉及将VEGF定向疗法与检查点抑制相结合，癌症疫苗，磷脂酰丝氨酸，YIV-906以及溶瘤和免疫治疗牛痘病毒。
概括

经过将近10年的休眠期之后，aHCC潜在的全身治疗选择的清单正在迅速增长。鉴于来自IMbrave150试验的有希望的数据，现在将atezolizumab和贝伐单抗联合使用是新的一线疗法。我们讨论了景观的变化，aHCC中新的二线和三线系统治疗以及正在进行的包括联合疗法在内的新型药物的临床试验。

StephenW

https://link.springer.com/articl ... c_springer_20210212